하부 호흡기 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 질환 유형별, 약제 클래스별, 투여 경로별, 최종사용자별, 지역별, 경쟁(2020-2030년)

The Global Lower Respiratory Tract Therapeutics Market was valued at USD 36.04 billion in 2024 and is projected to reach USD 58.98 billion by 2030, registering a Compound Annual Growth Rate (CAGR) of 8.53%. This market growth is driven by key factors such as the rising prevalence of respiratory diseases like pneumonia, bronchitis, and chronic obstructive pulmonary disease (COPD). The increasing global burden of these conditions, particularly among vulnerable groups like the elderly and immunocompromised individuals, has fueled the demand for effective treatment options. Additionally, urbanization, exposure to environmental pollutants, and higher smoking rates in many regions are further aggravating the incidence of these diseases, which in turn drives the need for therapeutics to address both acute and chronic respiratory infections. The expansion of healthcare infrastructure, especially in developing regions, has also enhanced the accessibility of diagnoses and treatments, contributing to a growing market for respiratory therapeutics.

Key Market Drivers:

Rising Prevalence of Respiratory Disorders The global healthcare landscape is seeing a notable rise in respiratory disorders, particularly lower respiratory tract conditions. Disorders such as chronic obstructive pulmonary disease (COPD), asthma, pneumonia, and bronchitis are becoming more widespread, leading to heightened demand for effective therapeutic solutions. Lower respiratory tract conditions, which significantly affect lung function and overall quality of life, are among the most prevalent and debilitating. These conditions are becoming increasingly common, driven by factors such as urbanization, pollution, tobacco use, and sedentary lifestyles, alongside an aging population more susceptible to respiratory health issues.

Key Market Challenges:

Competition from Generic Drugs The market for lower respiratory tract therapeutics faces considerable challenges from intense competition and the growing availability of generic drugs. As branded therapies become established, generic alternatives often enter the market, offering more cost-effective options for patients. This price competition places pressure on pharmaceutical companies, particularly those marketing patented treatments, as generics provide comparable therapeutic effects at a much lower cost. The widespread use of generic drugs plays a pivotal role in reducing healthcare costs, posing a challenge for branded drug manufacturers to retain market share.

Key Market Trends:

Shift Towards Targeted Therapies There is a significant trend toward the development of targeted therapies in the global lower respiratory tract therapeutics market. This shift is driven by advancements in molecular biology and a deeper understanding of disease mechanisms. Targeted therapies aim to address the root causes of diseases such as COPD and asthma, rather than just alleviating symptoms. For example, biologic agents like monoclonal antibodies are being developed to target specific inflammatory molecules such as interleukins, which are integral in diseases like asthma and COPD. These treatments offer enhanced precision by directly addressing the underlying mechanisms of disease.

Key Market Players:

• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Pfizer Inc.
• GSK plc
• Novartis AG
• AstraZeneca Inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.

Report Scope:

This report segments the Global Lower Respiratory Tract Therapeutics Market into the following categories, with detailed industry trends:

By Disease Type:

• Asthma
• COPD
• Pneumonia
• Tuberculosis
• Bronchitis
• Others

By Drug Class:

• Antibiotics
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Cough Suppressants
• Nasal Decongestants
• Others

By Route of Administration:

• Oral
• Parenteral
• Others

By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

By Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia-Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape:

Company Profiles: This section provides a detailed analysis of the major companies operating in the Lower Respiratory Tract Therapeutics Market.

Available Customizations:

The Global Lower Respiratory Tract Therapeutics Market report offers customizations tailored to the specific needs of a company. The following customization options are available:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Applications
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Lower Respiratory Tract Therapeutics Market

5. Voice of Customer

6. Global Lower Respiratory Tract Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type (Asthma, COPD, Pneumonia, Tuberculosis, Bronchitis, Others)
  • 6.2.2. By Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs, Cough Suppressants, Nasal Decongestants, Others)
  • 6.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 6.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centres, Others)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map

7. Asia Pacific Lower Respiratory Tract Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Asia Pacific: Country Analysis
  • 7.3.1. China Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. India Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. Australia Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Japan Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. South Korea Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Europe Lower Respiratory Tract Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Spain Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. United Kingdom Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. North America Lower Respiratory Tract Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. Mexico Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. Canada Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. South America Lower Respiratory Tract Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Middle East and Africa Lower Respiratory Tract Therapeutics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Disease Type
  • 11.2.2. By Drug Class
  • 11.2.3. By Route of Administration
  • 11.2.4. By End User
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Lower Respiratory Tract Therapeutics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Disease Type
      • 11.3.1.2.2. By Drug Class
      • 11.3.1.2.3. By Route of Administration
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Lower Respiratory Tract Therapeutics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Disease Type
      • 11.3.2.2.2. By Drug Class
      • 11.3.2.2.3. By Route of Administration
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Lower Respiratory Tract Therapeutics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Disease Type
      • 11.3.3.2.2. By Drug Class
      • 11.3.3.2.3. By Route of Administration
      • 11.3.3.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Lower Respiratory Tract Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

• 17.1. F. Hoffman - La Roche Ltd
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (In case of listed companies)
  • 17.1.5. Recent Developments
• 17.2. Teva Pharmaceutical Industries Ltd.
• 17.3. Sanofi S.A
• 17.4. Pfizer Inc.
• 17.5. GSK plc
• 17.6. Novartis AG
• 17.7. AstraZeneca
• 17.8. Johnson & Johnson
• 17.9. Sun Pharmaceutical Industries Ltd.
• 17.10. Merck & Co., Inc

18. Strategic Recommendations

19. About Us & Disclaimer